EHA 2011
Links to reports filed by C.A. Simoneau from EHA COngress 2011
My Report From EHA – What has me so Excited!
The Changing Landscape in CML Therapy: New Treatment Goals and Choices
Optimizing Patient Outcomes to CML Treatment in 2011
CML Education Session – T. Holyoake
CML Education Session – A. Hochhaus
CML Education Session – H. Kantarjian
CML Clinical session Saturday – 24 months follow up Nilotinib
CML Clinical session Saturday – Bosutinib follow up ( BELA trial)
CML Clinical session Saturday – BCR ABL KD Mutations
CML Biology Session Saturday – PP2A as a therapeutic target
CML Biology Session Saturday – Hedgehog inhibitor combined with nilotinib
CML Biology Session Saturday – Prognosticability of enhanced Hh pathway
CML Biology Session Saturday – CIP2A inhibits PP2A and leads to BC
CML Biology Session Saturday – Prognosticability of LSC in BM in de Novo CML Patients
CML Clinical 2 Sunday – A new Prognostic Score EUTOS
CML Clinical 2 Sunday – DASISION 24 months follow up
CML Clinical 2 Sunday – Omacetaxine treatment survival compared to Historical Data
CML Clinical 2 Sunday – KIR2DS1 prognositicability
CML Clinical 2 Sunday – Stopping Dasatinib or Nilotinib in CML CP